GlassScriptPhysician profile
Stephen P Toth
NPI 1013588342
$2,020.82
in general payments reported to CMS, 2019-2025
22 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $31.01 · 2024: $381 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,861 · Education: $36.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.70 |
| Education | $36.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $958.93 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $141.80 | 2025 | Winrevair |
| Becton, Dickinson and Company | $109.32 | 2025 | Hemosphere |
| Jazz Pharmaceuticals INC. | $96.25 | 2024-2025 | |
| Insmed, INC. | $89.07 | 2025 | Arikayce |
| United Therapeutics Corporation | $85.93 | 2022 | |
| Amgen INC. | $65.91 | 2024-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.02 | 2025 | Ofev |
| Viatris Specialty LLC | $49.45 | 2025 | Yupelri |
| Genzyme Corporation | $45.39 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $45.17 | 2025 | Dupixent |
| Baxter Healthcare | $37.20 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Actelion Pharmaceuticals US, INC. | $34.57 | 2023-2024 | Opsumit, Uptravi |
| Verona Pharma, INC. | $34.17 | 2025 | Ohtuvayre |
| Abiomed | $30.86 | 2024 | Impella |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $30.34 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $24.36 | 2025 | Glassia |
| Lilly USA, LLC | $20.72 | 2022 | |
| Ambu INC. | $20.46 | 2025 | |
| Abbvie INC. | $17.24 | 2022 | |
| Glaxosmithkline, LLC. | $15.96 | 2025 | Nucala |
| Pfizer INC. | $12.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Toth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.